Use of an organic combination of Therapeutic compounds for the manufacture of a Medicament, a Therapeutic Agent, and a Pharmaceutical composition

摘要

A combination of at least two combinations of therapeutic ingredients selected from the group: (I) the target country of the AT1 receptor, or the target country of the AT1 receptor, plus a diuretic, or, in each case, a medically acceptable salt, (II) an hmg-co-a reductase inhibitor or a pharmaceutically acceptable salt, and (III) an ACE inhibitor or a pharmaceutically acceptable sa characterized by the production of a drug to prevent, delay development or treat a disease or condition selected from the following groups: It's blood fat and degreasing1. Myocardial infarction, insulin resistance and type X syndrome, type 2 diabetes, obesity, kidney disease, renal failure, hypothyroidism, survival after myocardial infarction, coronary heart disease, hypertension in the elderly, and family milk fat allergy; And immediately redesign the ultraluminosity (comprehensive anti-corrosion effect)All of these diseases or conditions related to or without hypertension are used to prevent, delay development or treat embolism, erectile dysfunction, and vascular diseases for the production of drugs, therapeutics, and pharmaceutical ingredients.